Relative Bioavailability Study Of Two Lincomycin Hydrochloride Hard Gelatinous Capsule
Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
To assess the relative bioavailability of two different batches of Frademicina® drug product,
containing 500 mg lincomycin hydrocloride, manufactured by Pfizer Laboratories Ltd. The
formulations' comparative bioavailability after oral administration will be assessed based on
the statistical comparisons of the relevant pharmacokinetic parameters, obtained from the
drug concentrations in the blood. The lincomycin hydrocloride concentration will be measured
by a proper and validated analytical method.